Introduction: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration. Methods: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64 years with schizophrenia in Sweden (N = 29,823 in total; N = 4603 in the incident cohort). Multivariate Cox regression models were adjusted for clinical and sociodemographic covariates. Sensitivity analyses with the incident cohort were conducted to control for survival bias. Results: During the mean follow-up of 5.7 years, 2515 patients (8.4%) died. During the maximum follow-up (7.5 years), the lowest cumulative mortality was observed for second generation (SG) long-acting injection (LAI) use (7.5%). Adjusted hazard ratios (aHRs) compared to SG LAI use were 1.37 (95%CI 1.01-1.86) for first generation (FG) LAIs, 1.52 (1.13-2.05) for SG orals, 1.83 (1.33-2.50) for FG orals, and 3.39 (2.53-4.56) for nonuse of antipsychotics. Concerning specific agents, the lowest mortality was observed for once-monthly paliperidone LAI (0.11, 0.03-0.43), oral aripiprazole (0.22, 0.15-0.34), and risperidone LAI (0.31,. In pairwise comparison, LAIs were associated with 33% lower mortality than equivalent orals (0.67, 0.56-0.80). The results with incident cohort were consistent with the primary analyses. Conclusions: Among patients with schizophrenia, LAI use is associated with an approximately 30% lower risk of death compared with oral agents. SG LAIs and oral aripiprazole are associated with the lowest mortality.
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Introduction
Patients with schizophrenia have a 15-20 year shorter life expectancy than the general population (Laursen et al., 2014) , and side effects of antipsychotic medications are considered a putative cause for the excess mortality (Glassman and Bigger Jr., 2001; Liebzeit et al., 2001; Ray et al., 2001; Cheeta et al., 2004; Fergusson et al., 2005; Mackin et al., 2007; Ray et al., 2009; Stahl et al., 2009; Stone et al., 2009) . A systematic review suggested that gap in mortality compared with general population is even worsening and may be related to second generation antipsychotic use (Saha et al., 2007) . Meta-analysis and systematic reviews of randomized controlled trials (RCTs) suggest that this is not the case, since mortality is lower during use of antipsychotics than during placebo (Baxter et al., 2016; Khan et al., 2007 Khan et al., , 2013 . However, these trial results have been criticized because the duration of treatments is usually substantially longer for active than placebo arms. Also, trials lasting a few months are too short to assess fatal adverse events related to cumulative drug exposure leading to health problems such as weight gain or diabetes.
Several observational studies on large unselected cohorts have shown that mortality is lower during use of antipsychotic compared with no use (Tiihonen et al., 2006 (Tiihonen et al., , 2009 (Tiihonen et al., , 2011 (Tiihonen et al., , 2012 (Tiihonen et al., , 2016 Baandrup et al., 2010; Crump et al., 2013; Vanasse et al., 2016) . However, these studies either did not control for survival bias or had short follow-up periods which made it difficult to evaluate the comparative effectiveness Schizophrenia Research xxx (2017) xxx-xxx
